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ABSTRACT
Introduction Weaning from ventilation is a complex 
process involving several stages that include recognition 
of patient readiness to begin the weaning process, steps 
to reduce ventilation while optimising sedation in order not 
to induce distress and removing the endotracheal tube. 
Delay at any stage can prolong the duration of mechanical 
ventilation. We developed a multicomponent intervention 
targeted at helping clinicians to safely expedite this 
process and minimise the harms associated with 
unnecessary mechanical ventilation.
Methods and analysis This is a 20- month cluster 
randomised stepped wedge clinical and cost- effectiveness 
trial with an internal pilot and a process evaluation. It is 
being conducted in 18 paediatric intensive care units 
in the UK to evaluate a protocol- based intervention for 
reducing the duration of invasive mechanical ventilation. 
Following an initial 8- week baseline data collection period 
in all sites, one site will be randomly chosen to transition 
to the intervention every 4 weeks and will start an 8- week 
training period after which it will continue the intervention 
for the remaining duration of the study. We aim to recruit 
approximately 10 000 patients. The primary analysis will 
compare data from before the training (control) with that 
from after the training (intervention) in each site. Full 
details of the analyses will be in the statistical analysis 
plan.
Ethics and dissemination This protocol was reviewed 
and approved by NRES Committee East Midlands—
Nottingham 1 Research Ethics Committee (reference: 
17/EM/0301). All sites started patient recruitment on 5 
February 2018 before randomisation in April 2018. Results 
will be disseminated in 2020. The results will be presented 
at national and international conferences and published in 
peer- reviewed medical journals.
Trial registration number ISRCTN16998143.
InTRoduCTIon
On average more than 20 000 children are 
admitted to paediatric intensive care units 
(PICUs) in the UK and 65% of admissions to 
PICU require invasive mechanical ventilation 
(IMV) for acute respiratory failure.1 Weaning 
and extubation from IMV are key steps in 
the child’s recovery and indicate progres-
sion towards PICU discharge. Deferments in 
weaning impact on patient morbidity prolong 
PICU stay and bed availability.
Currently, there is no consensus on the 
optimal weaning approach from IMV in 
PICUs. Our feasibility study highlighted 
considerable variation in ventilator weaning 
practice: usually a slow reduction in ventilator 
support to a very low level prior to extubation 
and no test of early readiness for extuba-
tion on higher levels of support using a trial 
of spontaneous breathing.2 Furthermore, 
nurses’ roles are not optimally utilised to 
adjust ventilator settings due to lack of proto-
cols to guide ventilator weaning and discon-
tinuation.3 In many PICUs, very few nurses 
are engaged in weaning, most PICUs suspend 
changes to ventilator settings overnight and 
weaning only happens during the day.2
Strengths and limitations of this study
 ► Sedation AND Weaning In CHildren (SANDWICH) is 
the first large multicentre pragmatic randomised 
trial (approximately 10 000 children) evaluating a 
collaborative sedation and weaning protocol aimed 
at reducing the duration of invasive mechanical ven-
tilation in critically ill children.
 ► From inception, SANDWICH has had strong involve-
ment from medical and nursing staff, parents and 
patients, and a children’s research advisory group.
 ► The trial has an embedded cost- effectiveness and 
process evaluation.
 ► The primary outcome is patient relevant and was 
proposed by parents and children during feasibility 
work.
 ► A limitation may be the practicality of achieving all 
signed research and governance approvals to en-
able sites to start at the same time within the re-
quired start- up time frame.
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Weaning from ventilation involves: (1) recognition that 
the child is ready to begin the weaning process, (2) steps 
to reduce ventilation while optimising sedation in order 
not to induce distress and (3) removing the endotracheal 
tube. Delay at any stage can prolong the duration of IMV; 
therefore, an intervention targeted at helping clinicians 
to expedite this process safely should reduce the harms 
associated with IMV. However, the judgement and expe-
rience of clinicians are critical in guiding weaning from 
ventilation, as our feasibility study showed, there is wide 
variation in sedation and ventilator weaning practices, 
junior staff are rarely involved in the process and use of 
weaning protocols is rare.2
A Cochrane review of weaning protocols in mechanically 
ventilated children highlighted only three randomised 
trials.4 A two- centre trial (n=260), using an interven-
tion incorporating daily screening and a spontaneous 
breathing trial (SBT), demonstrated a significant reduc-
tion of 32 hours (95% CI: 8 to 56 hours) in duration of 
IMV without additional harms.5 The smaller pilot studies 
using computer- driven protocols showed non- significant 
effects on duration of IMV, but significant reductions 
in weaning times (106 hours, 95% CI: 28 to 184; and 
21 hours, 95% CI: 9 to 32).6 7 A recent paediatric multi-
centre cluster randomised trial in the USA (n=31 sites) 
evaluated a sedation weaning protocol that included 
an SBT and found no significant reduction in duration 
of IMV.8 However, the main focus of this intervention 
was the stringent sedative regimen (targeted sedation, 
arousal assessments, sedation adjustment every 8 hours 
and sedation weaning). In adults, a Cochrane review of 
protocolised weaning (17 trials) showed a 26% reduction 
in duration of IMV in favour of protocols and the most 
commonly used protocol was daily screening and SBT.9 
Although results from adults cannot be applied directly 
to the paediatric population, the use of SBT as a weaning 
strategy shows promise and the paediatric systematic 
review indicates clinical uncertainty that is worthy of 
further evaluation.
Various intensive care unit studies have reported asso-
ciations between rates of high interprofessional collab-
oration and lower patient mortality10 11 and improved 
clinician- to- clinician communication with reductions 
in length of stay.12 A team- led approach that improves 
engagement of all staff in early recognition of readi-
ness and preparation for weaning ventilation has the 
potential to reduce duration of IMV and PICU length 
of stay and relieve pressures for beds. As 65% of nurses 
employed in UK PICU are Band 5 (junior) nurses, this 
would greatly increase the nursing contribution to the 
weaning process.1 Our feasibility study identified very few 
policies that specifically addressed sedation and weaning 
guidelines and staff interviews confirmed that a strategy 
for weaning sedation and ventilation was an important 
priority in most PICUs.2 Staff also disclosed continuing 
uncertainty about readiness to wean, the benefits of an 
extubation readiness test and its potential impact on 
duration of IMV in the UK.
The Sedation AND Weaning In CHildren (SAND-
WICH) trial has the capacity to generate new knowledge 
on the intervention, its cost- effectiveness and the imple-
mentation process. First, it will be large enough to provide 
reliable evidence for or against a combined ventilator/
sedation weaning protocol allowing clear, strong recom-
mendations to be made on the use of this potentially 
low- cost intervention. Second, it will determine the main 
organisational and process factors considered important 
for ensuring the intervention is optimally implemented 
in PICU.
METhodS
Aim and objectives
The SANDWICH trial will evaluate the clinical and cost- 
effectiveness of a protocol- based intervention incor-
porating co- ordinated care in managing sedation and 
weaning ventilation in reducing the duration of IMV in 
children in PICU. Specific objectives are to determine if 
the intervention:
 ► Reduces the duration of IMV in children irrespec-
tive of their expected ventilation duration (short or 
prolonged).
 ► Reduces length of PICU and hospital stay
 ► Does not cause additional harm as assessed through 
review of adverse events and respiratory complications.
 ► Is cost- effective in the National Health Service.
 ► Is sustainable and acceptable to staff delivering care.
A process evaluation (PE) conducted alongside the trial 
will explore the processes involved in delivering the inter-
vention, in order to identify factors and the mechanisms 
of their interaction that may impact on trial outcomes.
Study design and setting
 Setting
SANDWICH is a cluster randomised stepped wedge trial 
in 18 NHS PICUs. Participating PICUs provide clinical 
audit data to the Paediatric Intensive Care Audit Network 
(PICANet) database ( www. picanet. org. uk). PICUs will 
be eligible if they agree to nominate local champions, 
comply with the protocolised weaning intervention and 
staff document a willingness to participate in training.
 Design
The stepped wedge design involves sequential randomised 
rollout of the intervention over 4- week time periods 
(see figure 1). Randomisation will be conducted at the 
hospital site (cluster) level. In general, there is one PICU 
per site. In one site, there will be two PICUs participating. 
The site will be treated as one cluster for the purpose of 
randomisation, and the pair will be randomised to cross 
from control to intervention together to avoid interven-
tion contamination within the site. In the analysis, we will 
treat these two PICUs as two separate clusters. This trial 
requires that all participating PICUs begin the control 
phase of the trial when the data collection period begins. 
There will be an initial 8- week period of baseline data 
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Figure 1 SANDWICH study flowchart. SANDWICH, Sedation AND Weaning In CHildren.
collection during which the PICU will not be exposed to 
the intervention. Subsequently, every 4 weeks, one site will 
be randomly selected to transition to the intervention and 
start an 8- week training period during which the interven-
tion will be rolled out. The PICU can neither be assumed 
to be exposed or not exposed during training so in these 
8- week periods no patients will be recruited. Once a PICU 
crosses over to the intervention, it will remain exposed to 
the intervention for the remaining duration of the study. 
After the last PICU has crossed over and has fully tran-
sitioned to the intervention, there will be a final 8- week 
period during which all PICUs will be fully exposed.
We have chosen the stepped wedge design over the 
conventional parallel cluster design for four main 
reasons. First, we have a limited number of clusters avail-
able (maximum 26 PICUs in the UK, but not all likely 
to agree to participate). With this limited number, the 
parallel design is infeasible as there are not sufficient 
clusters to allow detection of the important clinical effect. 
Second, feasibility work informed us that units are more 
likely to participate in the trial if they are guaranteed 
their unit will at some point receive the intervention.2 
Third, it would be infeasible and more costly to deliver 
the intervention simultaneously to all units randomised 
to the intervention in a parallel design. Less important 
factors in our decision process, but none- the- less benefits 
of this design are the ability to estimate treatment effect 
heterogeneity (over time and clusters) and it allows for 
the possibility that the intervention may be tweaked as the 
trial progresses. This is important as while the intervention 
will be clearly documented in accordance with TIDieR 
guidelines,13 an intervention that is allowed to adapt to 
its setting has the best chance of success. Fourth, if the 
intervention is found to be effective, knowledge transla-
tion will be easier as PICUs participating can potentially 
continue post- trial maximising the benefits of any effects 
to the NHS and patients.
 Randomisation
The study statistician will conduct the randomisation. Each 
PICU will be allocated a unique ID. At study commence-
ment, sites will be classified on size based on the number 
of children receiving IMV in the PICU recorded in the 
2017 PICANet database. Randomisation will be balanced 
on cluster size such that clusters will be randomised in 
blocks of size 4, with each block containing two large and 
two small clusters.
 Internal pilot study
An internal pilot in the first four sites randomised to the 
intervention will evaluate and report progress during the 
period from randomisation to training, during training 
and in the 8- week period after implementing the interven-
tion. Specifically, the following criteria will be monitored:
 ► Actual patient numbers/month of eligible children 
against predictions.
 ► Feasibility of data collection procedures.
 ► Percentage of parents opting out from allowing collec-
tion of their child’s data.
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 ► Delivery of training (target >80% of staff/unit trained 
by the end of the pilot period).
 ► Adherence to intervention components (target >75% 
by the end of the pilot period).
We will address criteria not achieved in pilot sites 
through offering support and further training as 
required. The pilot report will be shared with all sites. 
The report will inform any actions required in trial 
management and training to address the above criteria 
for all sites.
 Timeline
The total study duration will be 36 months to include 9 
months for start- up, 20 months for the trial and 7 months 
for close down.
Intervention
Sedation and ventilator weaning in standard care 
will follow current best practice; this is currently non- 
protocol- based and medically driven. Assessment and 
management of sedation and ventilator weaning will 
be according to usual practice. Sedation levels will be 
assessed and recorded with a validated sedation tool, and 
ventilator weaning will involve a slow reduction in venti-
lator support until low levels are achieved consistent with 
readiness for extubation.
The SANDWICH intervention comprises four 
components:
 ► Greater interprofessional collaboration at ward 
rounds including review of COMFORT scores, seda-
tive regimen and setting targets; and ventilation and 
setting ventilation goals.
 ► Sedation measurement using the COMFORT tool.
 ► Regular daily assessment of criteria for readiness to 
perform an SBT by bedside nursing staff.
 ► An SBT and if no distress, a discussion about the deci-
sion to extubate.
The intervention training will be delivered at sites by 
an implementation manager who will train the trainers 
(local champions, principal investigators and study- 
specific research nurses). Training will include an online 
course and face- to- face instruction. A full description 
of the intervention was available in the study- specific 
training manual that was only provided to PICUs during 
and after the training period to avoid influencing prac-
tice during the control phase. However, at the time of 
publication, we are now able to release full details of the 
intervention, which can be found at http://www. qub. ac. 
uk/ sites/ sandwich.
Patients
All patients admitted to participating PICUs will be 
screened against the eligibility criteria.
 Inclusion criteria
 ► All children (<16 years) receiving IMV.
 Exclusion criteria
 ► Children not expected to reach the primary endpoint 
(tracheostomy in situ; not expected to survive; treat-
ment withdrawal).
 ► Children who are pregnant, as documented in their 
medical notes.
 Consent
A non- confirmed deemed consent (opt- out) approach 
will be taken in this trial. On patient admission, leaflets will 
be provided to parents or legal representatives informing 
them that the PICU is involved in a study and that staff 
will collect anonymised patient- level information. Leaf-
lets will include contact details for more information or 
to request that their child’s data is not included in the 
analysis. Individual patient consent will not be confirmed 
with parents. This deemed consent approach is in line 
with guidance from the Ottawa Statement,14 feedback 
from proposed guidance on consent in cluster trials from 
the NHS Health Research Authority15 and was considered 
appropriate by parents and children during our feasibility 
work.16 Posters will be displayed in prominent areas to 
explain that a trial is taking place in the PICU.
 Patient withdrawal
Children may be withdrawn from data collection on the 
request of parents or legal representatives. If parents opt- 
out from the study before data have been collected, this 
will be noted on the screening log, which will be held 
at the PICU. Following enrolment, if children are with-
drawn, withdrawal will be recorded in the patient record 
and on PICANet. Data collected up to the point of with-
drawal will not be included in the analysis.
outcomes
 Primary outcome
The duration of IMV measured in hours from initiation 
of IMV (or admission if already intubated) until the first 
successful extubation (defined as still breathing sponta-
neously 48 hours following extubation).
 Secondary outcomes
 ► Incidence of successful extubation (defined 
as breathing spontaneously 48 hours following 
extubation).
 ► Number of unplanned extubations (defined as 
dislodgement of the endotracheal tube from 
the trachea, without the intention to extubate 
immediately).
 ► Number of reintubations.
 ► Total duration of IMV.
 ► Incidence and duration of postextubation use of non- 
invasive ventilation.
 ► Tracheostomy insertion.
 ► Postextubation stridor.
 ► Adverse events (eg, unplanned removal/dislodge-
ment of vascular access or non- vascular catheters, brad-
ycardia, hypoxia, cardiopulmonary resuscitation).
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Table 1 Patient data collection schedule
Baseline (at point of 
recruitment)
Control phase up to 90 
days or PICU discharge
Intervention phase 
up to 90 days or 
PICU discharge
Post PICU 
discharge
Patient characteristics √
Daily 8 am ventilator parameters √ √
Daily PCCMD √ √
Daily adverse events √ √
Outcomes √ √
2 hours prior to extubation, 
ventilator parameters and 
COMFORT score
√
SANDWICH intervention checklist √
Hospital discharge and status √
PCCMD, Paediatric Critical Care Minimum Data Set; PICU, paediatric intensive care unit; SANDWICH, Sedation AND Weaning In CHildren.
 ► PICU length of stay from admission to discharge (in 
days).
 ► Hospital length of stay from admission to discharge 
(in days).
 ► Mortality occurring within the ICU.
 ► Mortality occurring within the hospital.
 ► Cost per complication avoided at 28 days
Outcomes will be measured from patient admission up 
to 90 days or discharge (whichever is earlier). At the end 
of the 20- month enrolment period, data collection will 
continue for a maximum of 28 days.
data collection
The trial will collaborate with PICANet to make best 
use of the data collection infrastructure, which exists in 
PICUs in the UK. Participating PICUs routinely submit 
clinical data to PICANet to monitor activity and perfor-
mance. PICUs have full access to and ownership of the 
data. Data are validated on entry and centrally on the 
PICANet server. PICANet produce a download facility 
that allows participating PICUs to extract data required 
for SANDWICH, thus reducing the burden of data collec-
tion for research staff.
When submitting individual patient data to PICANet, 
research staff will indicate enrolled patients by adding a 
unique trial number. PICANet has implemented a facility 
to allow research staff in each PICU to download a pseu-
doanonymised data set of their data for checking and 
upload to the SANDWICH Clinical Trials Unit (CTU) as 
required. This pseudoanonymised data set download will 
not include patient identifiable information. Trial data 
will be transmitted from participating PICUs to the CTU 
electronically using a secure method.
Outcome and compliance data that are not captured by 
PICANet will be collected and recorded on an electronic 
case report form (CRF) by PICU research staff and will 
not include patient identifiable information.
Table 1 shows the patient data collection schedule. The 
following data are collected:
Patient characteristics (eligibility, study number, intu-
bation date/time, sociodemographics).
· Ventilator parameters (mode of IMV, fraction of 
inspired oxygen, positive end- expiratory pressure (PEEP), 
peak inspiratory pressure, ventilator rate, tidal volume 
and the level of pressure support above PEEP).
· Paediatric Critical Care Minimum Data Set.
· Adverse events
 ► SANDWICH intervention data (readiness to wean 
criteria, COMFORT, ward round targets).
 ► Study outcomes.
 ► Post- PICU discharge (hospital length of stay, destina-
tion postdischarge, hospital mortality).
AnAlySIS
Clinical evaluation
Baseline characteristics will be summarised by exposure 
and non- exposure to the intervention using summary 
statistics. PICUs will be classified as being exposed to the 
intervention on completion of the training period. The 
primary aim is to evaluate whether there is a difference 
in the duration of hours on ventilation before and after 
exposure to the intervention. We will use survival analysis 
(time to extubation) and estimate an HR for the inter-
vention effect. This means that higher HRs will signify 
success of the intervention.
We will know exact survival times (ie, times until 
successful extubation) for most children, but children 
who die on ventilation, are transferred to another unit, 
are not weaned before transitioning to the training phase 
or are not weaned by 90 days will not have a known 
extubation time. We will treat such events as censored 
observations, making the assumption that children who 
are censored for any of these reasons will have an extu-
bation time (ie, were or would have been removed from 
ventilation) greater than the time until they died or were 
transferred. These are plausible assumptions. In order 
to minimise any potential within cluster contamination, 
we will censor children when their PICU moves into the 
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transition phase. When the PICU moves into the inter-
vention phase, only new admissions will be included.
We will explore various models, but anticipate fitting 
a Cox proportional hazards model, perhaps with some 
treatment- by- covariate interaction to incorporate any 
non- proportionality. Allowance will be made for clus-
tering using a frailty term for each PICU (this is similar 
to a random effect in a mixed- effects model). We will also 
adjust for calendar time, since the intervention is sequen-
tially rolled- out. If a child is readmitted or transferred, 
they will be treated as new events and acknowledged 
within our analysis. Our primary estimate of the treat-
ment effect will be a cluster and time- adjusted HR along 
with 95% CIs. Time adjustment is essential because this is 
a stepped wedge trial.
Secondary analysis will adjust for individual and cluster 
level covariates (such as the adherence score) and these 
will be prespecified. Null hypotheses and analyses for 
secondary outcomes take a similar form to that for the 
primary outcome. Where outcomes are not survival times, 
analysis will use the generalised linear mixed model, 
reporting risk differences for binary outcomes and mean 
differences for continuous outcomes (all adjusting for 
cluster and time effects).
Full details of the analyses will be given in the statistical 
analysis plan.
Economic evaluation
A cost- effectiveness analysis will be performed from the 
perspective of the hospital to estimate the cost per compli-
cation avoided at 28 days. The occurrence of respiratory 
complications at 28 days will be measured.
We will estimate total hospital costs until 28 days for 
each participant by applying appropriate unit costs from 
the NHS Schedule of Reference Costs17 to resource use 
data collected prospectively via the CRF or PICANet, as 
appropriate. Data on PICU resource use will be obtained 
via PICANet through the routine collection of the Paedi-
atric Critical Care Minimum Data Set (PCCMDS). The 
PCCMDS consists of items recorded for each PICU bed- 
day that can be used to define the level of care and appro-
priate healthcare resource group. For patients discharged 
from hospital before 28 days, data on any PICU readmis-
sions within 28 days will come from PICANet but data 
on readmissions to general hospital wards will not be 
collected. This is expected to lead to only minimal data 
loss, as the readmission rate within 30 days in a similar 
paediatric population was low (5%), with a mean hospital 
length of stay of less than 1 day.18
We will summarise hospital service use, costs and respi-
ratory complications using descriptive statistics. Multilevel 
mixed- effects regression modelling will be used for total 
costs and respiratory complications. We will adjust for 
calendar time and clustering, ensuring consistency with 
the other models being constructed as part of the main 
analysis. We will estimate adjusted incremental (differen-
tial) total costs and adjusted incremental effects (respi-
ratory complications). Standard methods will be used to 
explore and display uncertainty in the cost- effectiveness 
data including scatterplots on the cost- effectiveness plane 
and cost- effectiveness acceptability curves. Since there is 
no generally accepted threshold value for cost per respi-
ratory complication avoided, a range of plausible thresh-
olds will be explored. Sensitivity analysis will assess the 
robustness of the cost- effectiveness results to changes in 
key parameters. Since the time horizon of the analysis is 
less than 1 year, it will not be necessary to discount costs 
and effects.
PRoCESS EvAluATIon
Aim and objectives
The PE will explore the processes involved in delivering 
the intervention. The specific objectives are:
 ► To establish the extent to which the intervention is 
implemented as intended (implementation fidelity), 
over time and across different PICU.
 ► To ascertain how PICU staff understand and respond 
to the intervention, over time and across different 
PICU.
 ► To explore the context over time and across different 
PICU and determine factors (including managerial, 
economic, organisational and work level) that affect 
implementation.
data collection methods
The methods used for the PE will be:
 ► Initial site visits to obtain information on context and 
usual practice collected through interviews and/or 
focus groups with staff involved in the implementa-
tion and delivery of the intervention, using purposive 
sampling to obtain a range of participants according 
to grade and profession.
 ► Telephone interviews with research staff and local 
champions in the intervention phase to obtain 
information regarding the implementation process, 
acceptability of the intervention, barriers and clinical 
decisions affecting the use of the intervention.
 ► Final site visits to undertake individual and/or focus 
group interviews with a purposive sample of staff 
involved in implementation or intervention delivery. 
Interviews will explore clinician understanding and 
experiences, including those relating to barriers 
and facilitators to the delivery and receipt of the 
intervention.
data analysis methods
Data from the PE will be analysed using the framework 
approach.19 A sample of textual data will be reviewed and 
double- coded by another independent member of the 
research team to ensure confirmability and trustworthi-
ness. The integration of process and trial outcome data 
and subsequent analyses will be secondary and explana-
tory, and separate from the primary effectiveness analysis. 
The qualitative evidence will be systematically combined 
with outcome data to identify the processes mediating 
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Figure 2 Power curve. CAC, cluster autocorrelation; ICC, intracluster correlation.
protocol implementation, receipt and setting and observed 
outcomes.
SAMPlE SIzE
The primary aim of this study is to determine whether 
the intervention can reduce the average number of 
hours on ventilation in eligible children. To inform the 
power calculation, we used PICU admissions data for 
the years 2014 to 2016 from units participating in the 
trial to determine parameters to inform the sample size 
calculation. The expected sample size is 9520 based on 
an average cluster size of 28 patients per 4- week block. 
In this trial, duration of ventilation is censored at the 
point of transitioning from the control to the training 
period, discharge to another hospital, at 90 days, death 
and receiving a tracheostomy, so applying censoring to 
this data set provided us with a homogeneous population 
that more accurately reflected the trial population. The 
mean duration of mechanical ventilation was 5.8 (SD 9.6) 
days and an Intracluster Correlation (ICC) of 0.005 (95% 
CI: 0.001 to 0.01). It is postulated that a reduction of 1 day 
on ventilation is both clinically important and achievable. 
While our primary analysis will be a survival analysis, no 
methodology currently exists to determine power in a 
stepped wedge trial for this outcome type. We therefore 
determined the power available assuming a continuous 
outcome. This is expected to be a conservative approach 
meaning that it should have slightly underestimated the 
power not having allowed for the time to event nature of 
the data.
The cluster sample size app (https:// clusterrcts. shin-
yapps. io/ rshinyapp) was used to update the sample size 
calculation given this information. Using this app and 
for the actual design of the trial (using the actual infor-
mation on the number of clusters and number of steps) 
and using the following assumptions: no. clusters per 
sequence=1, ICC=0.005 (with consideration across the 
range 0.001 to 0.01), an exchangeable correlation struc-
ture, mean difference=1, SD=9.6, at 5% significance level, 
the power is approximately 80% for a cluster size of 28 
(figure 2).
PATIEnT And PuBlIC InvolvEMEnT
We undertook consultation interviews with parents, a 
15- year- old PICU survivor and 13 young people who were 
members of the National Institute for Health Research 
(NIHR) Clinical Research Network: Children, Young 
Person’s Advisory Group about the proposed trial. Their 
views have contributed to the choice of patient relevant 
outcomes and informed the approach to consent. The 
consultation work was funded by the Northern Ireland 
Health and Social Care Research and Development Division 
and aided by Jenny Preston, Consumer Liaison Manager for 
the NIHR- Children Research Network. We secured patient 
and young people’s continued involvement to provide 
advice on study design, implementation, parent and child 
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information leaflets, assistance with preparation of educa-
tional materials and dissemination of findings. Father and 
son, Lewis and Archie Veale (now 18 years), agreed to be on 
the Trial Steering Group for this study. They have first- hand 
experience of the difficulties of ventilator weaning (Archie 
spent 8 weeks in PICU in 2014).
EThICS, ovERSIghT And dISSEMInATIon
oversight
The Northern Ireland CTU (NICTU) will manage the trial. 
The Trial Management Group, chaired by the chief inves-
tigator, will meet monthly and have responsibility for the 
day- to- day operational management of the trial. The Trial 
Steering Committee (TSC) will meet approximately every 6 
to 12 months and provide oversight for the conduct of the 
study on behalf of the Funder (National Institute for Health 
Research) and Sponsor (Queen’s University Belfast). The 
Data Monitoring Committee (DMC) will meet approxi-
mately every 6 to 12 months and will safeguard the rights, 
safety and well- being of trial participants; monitor data and 
make recommendations to the TSC on whether there are 
any safety reasons why the trial should not continue; and 
monitor overall study conduct to ensure validity and integ-
rity of the study findings.
dissemination
We will publish findings from this study in a timely and rele-
vant manner to influence health service policy to deliver 
public benefit. Our dissemination strategy targets a variety 
of service users including: (1) the UK paediatric intensive 
care community (trial updates at the PICS Study Group 
meetings); (2) the wider paediatric intensive care commu-
nity (presentations at national and international meetings; 
publications in high- quality peer- reviewed open access jour-
nals); (3) the public via a final report in the NIHR Health 
Technology Assessment (HTA) journal and national parent 
support and liaison groups, via social media and through 
the PICS families group; and (4) NHS managers and 
commissioners if the study supports a change of practice.
TRIAl STATuS
This paper presents the protocol (version 5, 12 March 
2019). The trial began on 5 February 2018. At the time of 
first manuscript submission, data collection for the trial 
was ongoing and due to be complete in October 2019. 
The trial results will be disseminated in 2020 through 
presentations at national and international conferences 
and publication in peer- reviewed medical journals.
dATA STATEMEnT
The data generated and/or analysed during the SAND-
WICH trial are not yet publicly available due to the 
ongoing nature of the trial. When the trial is complete, 
data sets will be available from the chief investigator on 
reasonable request and arrangements will be made to 
deposit them in a suitable online repository.
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